For research use only
| Cat No. | ABC-TC0505 |
| Product Type | Human Bone Cancer Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Bone |
| Product Code | KHOS-NP; KHOS NP; KHOSNP; R-970-5; KH |
This cell line was derived from the HOS cell line (TE-85) by transformation using Kirsten murine sarcoma virus (Ki-MSV).
KHOS‑NP is a human osteosarcoma tumor cell line derived from the HOS (TE‑85) parental line through transformation by Kirsten murine sarcoma virus (Ki‑MSV), originally established from bone tissue of a 13‑year‑old Caucasian female with osteogenic sarcoma. The cells display adherent, fibroblast-like and epithelial‑like morphology and exhibit a high saturation density and high plating efficiency in soft agar, characteristics consistent with transformed osteosarcoma cells. KHOS-NP carries Ki-MSV sequences but does not produce replication-competent infectious virus particles under standard culture conditions; in in vivo models, subcutaneous inoculation typically results in tumor formation within approximately 2-4 weeks with high frequency under standard assay conditions, reflecting robust tumorigenicity. The line is also used for production of murine sarcoma virus (MSV) pseudotypes in virology studies. Genetic and expression features reported for KHOS‑NP are based on published literature and database records. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV‑1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | KHOS-NP; KHOS NP; KHOSNP; R-970-5; KH |
| Species | Human |
| Cat.No | ABC-TC0505 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Bone |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Bone Cancer Cell Lines |
KHOS‑NP is used as an in vitro model of human osteosarcoma for studies of bone tumor cell proliferation, transformation, and oncogenic signaling. It supports investigation of anchorage‑independent growth, tumorigenicity mechanisms, viral pseudotype production, and comparative analyses with other sarcoma lines. The line is also employed in drug response studies, including evaluation of antiproliferative and differentiation‑modulating agents in osteosarcoma research.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
